Diabetic neuropathy

Nevro announces launch of HFX Connect™ in Europe and CE marking of expanded labelling for the HFX™ SCS system.

Retrieved on: 
Thursday, August 10, 2023
PDN, CE, NSBP, Diabetic neuropathy, Quality of life, CMO, Human back, Pain, Patient, HFX, Chronic pain, NYSE, SCS, Medical device, Omnia

REDWOOD CITY, Calif., Aug. 10, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) has announced today the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropathy, PDN and Non-Surgical Back Pain, NSBP) for the HFX SCS system.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 10, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) has announced today the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropathy, PDN and Non-Surgical Back Pain, NSBP) for the HFX SCS system.
  • In addition, the latest regulatory approval includes expanded labelling for HFX.
  • HFX is now the world's first and only SCS therapy with approved CE mark for pain relief and sensory improvement in PDN patients.
  • The market release of HFX Connect in Europe follows commercial launch in the USA and Australia.

Neuragenex Expands to Open New Illinois Location, Giving More People Access to its Innovative Approach to Chronic Pain Management

Retrieved on: 
Tuesday, August 8, 2023
Aurora, Heart, Communication, Travel, Diabetic neuropathy, Quality of life, Heroin, Opioid, Pain, Death, Abuse, Patient, Nervous system, Pain management, Wheaton, Health, Chronic pain, Poultry farming, Canal, Dentistry, Electroanalgesia

With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.

Key Points: 
  • With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.
  • Specializing in non-pharmaceutical and non-invasive pain management treatments, Neuragenex recognizes that traditional pain management approaches often rely on medications, surgeries, or therapies with limited efficacy.
  • Patients who have experienced Neuragenex's innovative approach to chronic pain management have reported remarkable success and transformative outcomes.
  • Committed to pushing the boundaries of pain management, Neuragenex continuously aims to provide relief and improve the lives of individuals suffering from persistent pain.

Neuragenex Expands to Open New Utah Location, Giving More People Access to its Innovative Approach to Chronic Pain Management

Retrieved on: 
Tuesday, August 8, 2023
Heart, Salt Lake, Communication, Travel, Diabetic neuropathy, Quality of life, SALT, Heroin, Opioid, Pain, Death, Abuse, Patient, Nervous system, Pain management, Health, Chronic pain, Dentistry, Nursing, Electroanalgesia

With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.

Key Points: 
  • With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.
  • Despite this seemingly common goal, what differentiates Neuragenex however is their commitment to developing innovative solutions that go beyond conventional pain management approaches.
  • Specializing in non-pharmaceutical and non-invasive pain management treatments, Neuragenex recognizes that traditional pain management approaches often rely on medications, surgeries, or therapies with limited efficacy.
  • Patients who have experienced Neuragenex's innovative approach to chronic pain management have reported remarkable success and transformative outcomes.

Neuragenex Expands to Open New Georgia Locations, Giving More People Access to its Innovative Approach to Chronic Pain Management

Retrieved on: 
Tuesday, August 8, 2023
Heart, Communication, Travel, Diabetic neuropathy, Georgia Department of Public Health, Quality of life, McDonough, Opioid, Pain, Death, Abuse, Public health, Bluffdale, Utah, Georgia Department of Economic Development, Patient, Nervous system, Pain management, Health, Chronic pain, Fentanyl, Poultry farming, Dentistry, Pharmaceutical industry, Nursing, Electroanalgesia, Atlanta

With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.

Key Points: 
  • With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.
  • Despite this seemingly common goal, what differentiates Neuragenex however is their commitment to developing innovative solutions that go beyond conventional pain management approaches.
  • Specializing in non-pharmaceutical and non-invasive pain management treatments, Neuragenex recognizes that traditional pain management approaches often rely on medications, surgeries, or therapies with limited efficacy.
  • Committed to pushing the boundaries of pain management, Neuragenex continuously aims to provide relief and improve the lives of individuals suffering from persistent pain.

Neuragenex Expands to Open New Texas Location, Giving More People Access to its Innovative Approach to Chronic Pain Management

Retrieved on: 
Tuesday, August 8, 2023
Heart, Communication, Travel, Diabetic neuropathy, Quality of life, Opioid, Pain, Death, Abuse, Bluffdale, Utah, Patient, Nervous system, Pain management, Health, Chronic pain, Fentanyl, Dentistry, Electroanalgesia, WACO

With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.

Key Points: 
  • With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.
  • Despite this seemingly common goal, what differentiates Neuragenex however is their commitment to developing innovative solutions that go beyond conventional pain management approaches.
  • Specializing in non-pharmaceutical and non-invasive pain management treatments, Neuragenex recognizes that traditional pain management approaches often rely on medications, surgeries, or therapies with limited efficacy.
  • Patients who have experienced Neuragenex's innovative approach to chronic pain management have reported remarkable success and transformative outcomes.

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

Retrieved on: 
Wednesday, August 2, 2023
Diabetic neuropathy, Interim, Research, Acquisition, Quality control, Pharmaceutical industry

BOSTON, Aug. 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has entered into a term sheet with MThera Pharma Co., Ltd. (MTHERA) which provides for the terms under which NeuroBo will out-license the worldwide rights, outside of Korea, for NB-01 for the treatment of painful diabetic neuropathy to MTHERA.

Key Points: 
  • BOSTON, Aug. 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has entered into a term sheet with MThera Pharma Co., Ltd. (MTHERA) which provides for the terms under which NeuroBo will out-license the worldwide rights, outside of Korea, for NB-01 for the treatment of painful diabetic neuropathy to MTHERA.
  • The term sheet allows MTHERA to conduct research in order to seek new patents for NB-01 and conduct clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States for the future commercialization of NB-01.
  • The financial terms of the term sheet, which are binding, were not disclosed.
  • "Since acquiring the cardiometabolic assets DA-1241 and DA-1726, we have focused diligently to evaluate potential out-licensing and acquisition opportunities for our four legacy therapeutic programs, ANA001, NB-01, NB-02 and Gemcabene, and this term sheet with MTHERA is a testament to those efforts.

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

Retrieved on: 
Wednesday, July 19, 2023
Gordon Research Conferences, Diabetic neuropathy, Cancer, National Center for Advancing Translational Sciences, Doctor of Philosophy, Transcriptome, Pain, Gordon, Food and Drug Administration Amendments Act of 2007, FABP, Therapy, IND, Conference, Food, Pharmaceutical industry

https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/

Key Points: 
  • https://www.grc.org/cannabinoid-function-in-the-cns-conference/2023/
    “I am looking forward to sharing our data on the potential applications of inhibiting fatty acid binding proteins from our extensive library of compounds,” said Professor O’Sullivan.
  • “We are particularly excited to share new information on the effects of our FABP inhibitor ART26.12 on not only cannabinoid receptors, but other receptors implicated in pain signaling, as well as lipidomic and transcriptome data that help us understand how ART26.12 elicits its effects in peripheral neuropathies.”
    Professor O’Sullivan’s presentation on Thursday, July 20, 2023 includes data on ART26.12, Artelo’s lead compound targeting a variety of painful neuropathies, as well as the potential of FABP inhibitors beyond peripheral neuropathies.
  • ART26.12 was selected from Artelo’s platform of inhibitors to FABPs as its first candidate drug.
  • The Company recently announced it expects pre-IND meeting feedback on its IND planning and development strategy from the Food and Drug Administration during the third quarter of this year with the goal of initiating clinical development in early 2024.

TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes

Retrieved on: 
Thursday, July 13, 2023
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Dialysis, Gangrene, Pain, Urinary tract infection, A1C, Incidence, Patient, Risk, Insulin, Ulcer, Fasting, Pancreatitis, Diet, Urine, PBC, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, DPP4, Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, EGFR, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Blood, Erythema, Metformin, Swelling, Type, Moyamoya disease, Knee, Blood pressure, Medicine, Infection, Pyelonephritis, Food, Hospital, Fatal, Necrotizing fasciitis, Glomerular filtration rate, Diabetic ketoacidosis, Perineum, Calorie, SGLT2, Ketoacidosis, Acute kidney injury, Nausea, Bexagliflozin, Female, Pharmaceutical industry, Dietary supplement, Meat

BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.

Key Points: 
  • BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.
  • BRENZAVVY treatment can be initiated in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m2.
  • "We are excited to offer Brenzavvy to our patients with diabetes," said Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company.
  • "TheracosBio is breaking new ground by making this product available to consumers at a transparent, low price.

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, July 12, 2023
ACT, Part 1, Triple-negative breast cancer, TNBC, Index, Probability, HIV, VL, Pharmacy, Part, Diabetic neuropathy, DLT, Weakness, BOR, ART, Research, Observation, ASCO, Synthetic control method, EBITDA, Endometrial cancer, Patient, Treatment, Marathon Asset Management, Part Two, Viral load, MTD, SMR, Growth, Diagnosis, Toxic leukoencephalopathy, R, CD4, Ovarian cancer, American Conference, Hand, Conference, SD, Disease, PR, Safety, Prostate cancer, SORT1, Fine chemical, Pharmaceutical industry, Vaccine

For the second quarter of fiscal 2023, net sales of EGRIFTA SV® were $10,853,000 compared to $11,416,000 in the second quarter of fiscal 2022, representing a decrease of 4.9% year-over-year.

Key Points: 
  • For the second quarter of fiscal 2023, net sales of EGRIFTA SV® were $10,853,000 compared to $11,416,000 in the second quarter of fiscal 2022, representing a decrease of 4.9% year-over-year.
  • Trogarzo® net sales in the second quarter of fiscal 2023 amounted to $6,696,000 compared to $7,852,000 for the same quarter of 2022, representing a decrease of 14.7% year-over-year.
  • We ended the second quarter of fiscal 2023 with $25,369,000 in cash, bonds and money market funds.
  • In the second quarter of fiscal 2023, changes in operating assets and liabilities had a positive impact on cash flow of $4,643,000 (2022-positive impact of $10,701,000).

Back Pain & Joint Center of Texas Introduces New Neuropathy Treatments

Retrieved on: 
Friday, June 30, 2023
Back pain, Human, Diabetes, Diabetic neuropathy, Paresthesia, Weakness, Quality of life, Comprehensive examination, Patient, American College, Nerve, Chronic pain, Physical medicine and rehabilitation, Dentistry, Nursing, BCN

Conroe, Texas, June 30, 2023 (GLOBE NEWSWIRE) -- Back Pain & Joint Center of Texas is delighted to announce that new neuropathy treatments are now available.

Key Points: 
  • Conroe, Texas, June 30, 2023 (GLOBE NEWSWIRE) -- Back Pain & Joint Center of Texas is delighted to announce that new neuropathy treatments are now available.
  • At Back Pain & Joint Center of Texas , all treatments are overseen by providers who are certified in treating neuropathy , ensuring that patients receive the highest level of care in a professional and controlled environment.
  • Back Pain & Joint Center of Texas offers a unique combination of treatments that patients may not find in other clinics in the area.
  • Back Pain & Joint Center of Texas has changed  the lives of thousands of patients by helping them finally get the right treatment and relief for their neuropathy and disc related pain.